ArticleRMD open2022
Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease.
Article in RMD open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Lumbar spinal stenosis in axial spondyloarthritis and chronic low back pain: a cross-sectional magnetic resonance imaging study with clinical dimensions.Clinical rheumatology · 2026Article
- Association of Vaccination With COVID Outcomes in Pregnant People With Autoimmune Diseases: A Retrospective National Cohort Analysis.Arthritis care & research · 2026Article
- A Prospective Cohort Study of Hepatitis B Virus Vaccination in Pediatric Heart Transplant Recipients: Cellular and Humoral Immune Responses and the Role of Innate Immunity.The Pediatric infectious disease journal · 2026Article
- Single-cell transcriptome profile during the antibody decline phase following inactivated COVID-19 vaccination.Frontiers in cellular and infection microbiology · 2025Article
- Review
- Ixekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study.Rheumatology and therapy · 2024Article
- Effectiveness and Safety of the COVID-19 Vaccine in Patients with Rheumatoid Arthritis in a Real-World Setting.Vaccines · 2024Article
- Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases.JCI insight · 2024Observational
- Immunogenicity of Covishield vaccine in patients with autoimmune rheumatic diseases.Journal of family medicine and primary care · 2024Article
- COVID-19 Vaccine Effectiveness among Patients with Psoriatic Disease: A Population-Based Study.Vaccines · 2024Article
- A panel of janus kinase inhibitors identified with anti-inflammatory effects protect mice from lethal influenza virus infection.Antimicrobial agents and chemotherapy · 2024Article
- Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases.European journal of medical research · 2024Observational
- COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases.Vaccines · 2023Review
- Effect of DMARDs on the immunogenicity of vaccines.Nature reviews. Rheumatology · 2023Review
- Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases.The Journal of infectious diseases · 2023Article
- Article
- Should we stop methotrexate or not for vaccination?RMD open · 2023Article
- The Kinetics of Humoral and Cellular Responses after the Booster Dose of COVID-19 Vaccine in Inflammatory Arthritis Patients.Viruses · 2023Article
- Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non- to low-responders and B cell deficient rheumatic disease patients.Journal of autoimmunity · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe development of sufficient COVID-19 vaccines has been a big breakthrough in fighting the global SARS-CoV-2 pandemic. However, vaccination effectiveness can be reduced in patients with autoimmune rheumatic diseases (AIRD). The aim of this study was to identify factors that lead to a diminished humoral vaccination response in patients with AIRD.
methodsVaccination response was measured with a surrogate virus neutralisation test and by testing for antibodies directed against the receptor-binding-domain (RBD) of SARS-CoV-2 in 308 fully vaccinated patients with AIRD. In addition, 296 immunocompetent participants were investigated as a control group. Statistical adjusted analysis included covariates with a possible influence on antibody response.
resultsPatients with AIRD showed lower antibody responses compared with immunocompetent individuals (median neutralising capacity 90.8% vs 96.5%, p<0.001; median anti-RBD-IgG 5.6 S/CO vs 6.7 S/CO, p<0.001). Lower antibody response was significantly influenced by type of immunosuppressive therapy, but not by rheumatic diagnosis, with patients under rituximab therapy developing the lowest antibody levels. Patients receiving mycophenolate, methotrexate or janus kinase inhibitors also showed reduced vaccination responses. Additional negative influencing factors were vaccination with AZD1222, old age and shorter intervals between the first two vaccinations.
conclusionCertain immunosuppressive therapies are associated with lower antibody responses after vaccination. Additional factors such as vaccine type, age and vaccination interval should be taken into account. We recommend antibody testing in at-risk patients with AIRD and emphasise the importance of booster vaccinations in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.